According to the results of a meta-analysis aimed at analyzing the adverse events in castration-resistant prostate cancer patients receiving PARP inhibitors, anemia was the most frequently observed grade 3-4 toxicity (24.1%), followed by thrombocytopenia (6.7%), neutropenia (5.2%), fatigue (4.9%), leukopenia (3.4%). Here, PARP1 is linked to prostate carcinoma.